transplant rejection
CareDx Patents Deemed Invalid in Court Battle Against Natera, Eurofins Viracor
In a separate case in which CareDx and Natera are suing each other for false advertising, a court has set a trial date in late October.
The move opens the first non-oncology application for Oncocyte, which acquired the relevant cell-free DNA technology in its merger with Chronix this April.
Natera Q1 Revenues Grow 62 Percent
The company reported $152.3 million in total revenues for the quarter and said the number of tests it processed rose 48 percent from the prior-year quarter.
CareDx Q1 Revenues up 76 Percent
The company reported $67.4 million in total revenues for the quarter and said testing service revenues rose 89 percent year over year.
NY State Department of Health Approves Eurofins Viracor Transplant Rejection Tests
The Viracor TRAC donor-derived cell-free DNA test and TruGraf blood gene expression test both assess rejection status in kidney transplant recipients.
Mar 19, 2021
Mar 16, 2021
NephroSant Raises $16M in Series A Funding Round
Feb 25, 2021
Feb 24, 2021
CareDx Q4 Revenues Up 64 Percent
Jan 27, 2021
Oct 29, 2020
CareDx Q3 Revenues Up 58 Percent
Oct 7, 2020